Sorrento Therapeutics, Inc. Stock
Stocks
SRNE
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
OTC Markets
30/10/2026
|
5-day change | 1st Jan Change | ||
| 0.000300 USD | -.--% |
|
+200.00% | -88.46% |
| 03-18 | Semnur Pharmaceuticals, Inc. Announces CEO Changes, Effective March 13, 2026 | CI |
| 03-18 | Semnur Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 67.15M 60.14M 55.32M 50.12M 93.69M 6.38B 95.44M 660M 265M 3.35B 252M 247M 10.58B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 136M 125M 113M 212M 14.4B 216M 1.49B 598M 7.58B 569M 557M 23.89B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 week | +200.00% | ||
| 1 month | -62.50% | ||
| 3 months | -40.00% | ||
| 6 months | -40.00% | ||
| Current year | -88.46% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| Current year | 0 | | 0.01 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.25 |
| 5 years | 0 | | 7.4 |
| 10 years | 0 | | 19.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 01/04/2011 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2022 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 01/08/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +200.00% | -96.15% | -99.32% | 163K | |
| -0.62% | -1.87% | +42.87% | +67.17% | 63.77B | |
| -2.30% | +1.03% | +11.05% | +70.09% | 56.37B | |
| +0.61% | +1.98% | +20.07% | +102.31% | 54.62B | |
| -1.60% | -3.20% | +23.83% | +39.06% | 44.06B | |
| -1.52% | -1.09% | +17.63% | +101.50% | 42.11B | |
| +0.11% | +3.25% | +220.02% | +797.73% | 41B | |
| -5.25% | +25.71% | +99.84% | +88.75% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +47.05% | 32.82B | |
| -1.74% | +20.16% | -39.78% | +348.40% | 24.7B | |
| Average | -1.17% | +11.78% | +31.39% | +156.27% | 39.43B | |
| Weighted average by Cap. | -1.20% | +5.44% | +46.27% | +166.79% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 47.38M 43.58M 39.49M 73.82M 5.02B 75.2M 520M 209M 2.64B 199M 194M 8.33B | 62.84M 56.28M 51.77M 46.91M 87.68M 5.97B 89.32M 617M 248M 3.14B 236M 231M 9.9B |
| Net income | -428M -384M -353M -320M -598M -40.67B -609M -4.21B -1.69B -21.39B -1.61B -1.57B -67.47B | -573M -513M -472M -428M -799M -54.39B -814M -5.63B -2.26B -28.61B -2.15B -2.1B -90.23B |
| Net Debt | 111M 99.14M 91.19M 82.63M 154M 10.51B 157M 1.09B 437M 5.53B 415M 407M 17.44B | 84.53M 75.7M 69.63M 63.09M 118M 8.03B 120M 830M 333M 4.22B 317M 310M 13.31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | $0.000300 | -.--% | 10,988 |
| 29/10/26 | $0.000300 | -53.85% | 17,723 |
| 28/10/26 | $0.000650 | +550.00% | 403,304 |
| 27/10/26 | $0.000100 | -50.00% | 31,767 |
| 26/10/26 | $0.000200 | +100.00% | 72,025 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SRNE Stock
Select your edition
All financial news and data tailored to specific country editions
